The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)

Agents that have shown improvements in survival in mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents and palliative radiation continue to play an important role in the overall management of mCRPC. Given the complexity, variety and importance o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Can Urol Assoc J
Main Authors: Saad, Fred, Chi, Kim N., Finelli, Antonio, Hotte, Sebastien J., Izawa, Jonathan, Kapoor, Anil, Kassouf, Wassim, Loblaw, Andrew, North, Scott, Rendon, Ricardo, So, Alan, Usmani, Nawaid, Vigneault, Eric, Fleshner, Neil E.
Formato: Artigo
Idioma:Inglês
Publicado em: Canadian Medical Association 2015
Assuntos:
CUA Guidelines
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4455631/
https://ncbi.nlm.nih.gov/pubmed/26085865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.2526
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados